Immunolocalization of blocked and unblocked GP IIb-IIIa complexes in platelets during antithrombotic therapy with c7E3 Fab (ReoPro, abciximab)

被引：0
|
作者：
Nurden, A
Poujol, C
DurrieuJais, C
Besse, P
Jordan, R
Wagner, C
Nurden, P
机构：
[1] HOP CARDIOL,UMR 5533 CNRS,UNITE SOINS INTENS,IFR 4,PESSAC,FRANCE
[2] CENTOCOR LTD,MALVERN,PA
来源：
ATHEROSCLEROSIS | 1997年 / 134卷 / 1-2期
关键词：
D O I：
10.1016/S0021-9150(97)88959-9
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：184 / 184
页数：1
相关论文
共 41 条
  • [1] Labeling of the internal pool of GP IIb-IIIa in platelets by c7E3 Fab fragments (abciximab):: Flow and endocytic mechanisms contribute to the transport
    Nurden, P
    Poujol, C
    Durrieu-Jais, C
    Winckler, J
    Combrié, R
    Macchi, L
    Bihour, C
    Wagner, C
    Jordan, R
    Nurden, AT
    BLOOD, 1999, 93 (05) : 1622 - 1633
  • [2] Use of abciximab (c7E3 Fab, ReoPro) as an adjunct to balloon angioplasty
    McGregor, M
    Brophy, JM
    CANADIAN JOURNAL OF CARDIOLOGY, 1999, 15 (02) : 201 - 207
  • [3] Concept and clinical application of platelet glycoprotein IIb/IIIa inhibition with abciximab (c7E3 fab; ReoPro) for the prevention of acute ischemic syndromes
    Anderson, HV
    Jordan, RE
    Weisman, HF
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 1997, 3 (04) : 256 - 266
  • [4] Activation of platelets in platelet-rich plasma by rotablation is speed dependent and can be inhibited by abciximab (c7E3 Fab; ReoPro™)
    Williams, MS
    Coller, BS
    Vaananen, HJ
    Scudder, LE
    Marmur, JD
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 31 (02) : 237A - 237A
  • [5] Abciximab (c7E3 fab, ReoPro) with reduced heparin dosing during coronary intervention: Final results of the EPILOG trial
    Lincoff, AM
    Tcheng, JE
    Califf, RM
    Cabot, CF
    Miller, DP
    Booth, JE
    Montague, EA
    Anderson, KM
    Topol, EJ
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 29 (02) : 7396 - 7396
  • [6] Inhibition of angiogenesis and tumor growth by murine 7E3, the parent antibody of c7E3 Fab (abciximab; ReoPro™)
    Varner J.A.
    Nakada M.T.
    Jordan R.E.
    Coller B.S.
    Angiogenesis, 1999, 3 (1) : 53 - 60
  • [7] Incidence and outcome of thrombocytopenia following c7E3 Fab (abciximab) therapy
    Srivatsa, SS
    Grill, DE
    Melby, SJ
    Gastineau, DA
    Holmes, DR
    Bell, MR
    CIRCULATION, 1997, 96 (08) : 13 - 13
  • [8] Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy
    Berkowitz, SD
    Harrington, RA
    Rund, MM
    Tcheng, JE
    CIRCULATION, 1997, 95 (04) : 809 - 813
  • [9] Delayed profound thrombocytopenia after c7E3 Fab (Abciximab) therapy
    Jenkins, LA
    Lau, S
    Crawford, M
    Keung, YK
    CIRCULATION, 1998, 97 (12) : 1214 - 1215
  • [10] Activation of platelets in platelet-rich plasma by Rotablation is speed-dependent and can be inhibited by abciximab (c7E3 fab; ReoPro)
    Williams, MS
    Coller, BS
    Väänänen, HJ
    Scudder, LE
    Sharma, SK
    Marmur, JD
    CIRCULATION, 1998, 98 (08) : 742 - 748
12345